Although CoA stenting has become popular, some safety and technical issues still remain including risks of aneurysm formation, aortic rupture and vascular injury. We report the early clinical results of CoA stenting using the new ePTFE covered Advanta V12 LD stent (Atrium) in 2 centers. This stainless steel open-cell design stent comes premounted on 12, 14 and 16 mm balloons and requires a 9-11Fr delivery system. Two layers of a thin ePTFE membrane cover the stent in its inner and outer portions. From 09 to 12/2008, 13 patients (median age and weight: 14.5 years and 44.5kgs, respectively) with either native CoA (10) or ReCoa (3) underwent the procedure under general anesthesia. Balloons of a diameter sufficient to anchor the stent in the coarctation site were selected using the smallest available delivery system. Secondary dilation with larger diameter balloons was performed until the pressure gradient was less than 20mmHg and the stent was apposed to the isthmus wall.Coarctation diameter increased from 5.2±2.9 to 14.4±2.9 mm [p < 0.01]. Peak pressure gradient decreased from 29.4±13.2 to 2.2±3.4 mmHg [p < 0.001]. The stent achieved the desired diameter in all cases. There were no complications. At short-term median follow-up of 0.8 months all patients are alive and well with no evidence of recoarctation. These initial results show that the use of the new covered Advanta V12LD stent through a low profile delivery system is feasible, safe and effective in the immediate treatment of CoA. Long term follow up is required.